论文部分内容阅读
１６０ 例确诊为晚期肝细胞癌患者被随机分为Ａ、Ｂ与Ｃ 三组。Ａ 组应用特异性肿瘤细胞毒Ｔ 淋巴细胞（ ＣＴＬｓ） 加肝动脉化疗（ ＨＡＩＣ） 联合疗法；Ｂ组予ＣＴＬｓ 单一疗法；Ｃ组接受单一ＨＡＩＣ治疗。结果提示，联合疗法的总缓解率（ 完全反应＋ 部分反应） 与１ 、２ 、３ 年的生存率均比两种单一治疗高（ Ｐ＜ ０－０１） 。因此，ＣＴＬｓ 加ＨＡＩＣ联合疗法可能是治疗晚期肝细胞癌病人理想的治疗手段。
160 patients diagnosed with advanced hepatocellular carcinoma were randomly divided into A, B, and C groups. Group A was treated with specific tumor cytotoxic T lymphocytes (CTLs) combined with hepatic arterial chemotherapy (HAIC); Group B was given CTLs monotherapy; Group C was treated with a single HAIC. The results suggest that the overall remission rate (complete response + partial response) and the 1-, 2-, and 3-year survival rates of the combination therapy were higher than those of the monotherapy (P < 0-01). Therefore, CTLs plus HAIC combination therapy may be an ideal treatment for patients with advanced hepatocellular carcinoma.